Smith & Wesson Brands, CarMax And 3 Stocks To Watch Heading Into Friday
Portfolio Pulse from Lisa Levin
Smith & Wesson Brands reported better-than-expected Q4 results and raised its quarterly dividend. Apogee Enterprises is expected to report earnings of $0.90 per share on revenue of $354.77 million. CarMax is expected to have earned $0.79 per share on revenue of $7.53 billion. IonQ lifted its booking expectations for the year by 25%. Moderna submitted an application to the FDA for the authorization of its updated vaccine.
June 23, 2023 | 8:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IonQ lifted its booking expectations for the year by 25% to a new range of $45 million to $55 million, representing an increase of more than 100% year-over-year at the midpoint.
IonQ's increased booking expectations for the year indicate strong growth and positive business performance, which is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Smith & Wesson Brands reported better-than-expected Q4 results and raised its quarterly dividend from $0.10 to $0.12 per share.
Smith & Wesson Brands' better-than-expected Q4 results and increased dividend are likely to have a positive impact on its stock price in the short term as it indicates strong financial performance and shareholder value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Apogee Enterprises is expected to report quarterly earnings at $0.90 per share on revenue of $354.77 million.
Apogee Enterprises' earnings report is expected, but there is no indication of whether the results will be positive or negative. Therefore, the short-term impact on the stock price is neutral.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEUTRAL IMPACT
CarMax is expected to have earned $0.79 per share on revenue of $7.53 billion for the latest quarter.
CarMax's earnings report is expected, but there is no indication of whether the results will be positive or negative. Therefore, the short-term impact on the stock price is neutral.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEUTRAL IMPACT
Moderna submitted an application to the U.S. Food and Drug Administration for the authorization of its updated vaccine.
Moderna's submission of its updated vaccine application to the FDA is an important step, but the short-term impact on the stock price is neutral as the outcome of the authorization process is uncertain.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100